1001353-78-1Relevant articles and documents
Discovery of a 2,4-disubstituted pyrrolo-[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development
Wittman, Mark D.,Carboni, Joan M.,Yang, Zheng,Lee, Francis Y.,Antman, Melissa,Attar, Ricardo,Balimane, Praveen,Chang, Chiehying,Chen, Cliff,Discenza, Lorell,Frennesson, David,Gottardis, Marco M.,Greer, Ann,Hurlburt, Warren,Johnson, Walter,Langley, David R.,Li, Aixin,Li, Jianqing,Liu, Peiying,Mastalerz, Harold,Mathur, Arvind,Menard, Krista,Patel, Karishma,Sack, John,Sang, Xiaopeng,Saulnier, Mark,Smith, Daniel,Stefanski, Kevin,Trainor, George,Velaparthi, Upender,Zhang, Guifen,Zimmermann, Kurt,Vyas, Dolatrai M.
, p. 7360 - 7363 (2009)
This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development. 2009 American Chemical Society.
PYRROLOTRIAZINE KINASE INHIBITORS
-
, (2011/04/19)
The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.